Ace Therapeutics provides comprehensive solutions for drug-induced liver injury (DILI) to clients worldwide. Our scientists have over a decade of experience in the field of liver disease research. Based on our advanced technology platform and comprehensive service system, we can help you complete all studies of DILI with high quality and efficiency.
Drug-induced liver injury is the most common reason for withdrawing a drug from the market and/or issuing warnings and changes in use. It occurs in two main ways, predictable and unpredictable (i.e., idiosyncratic). The former tends to be drug dose-related and is reproducible in animal models. The vast majority, on the other hand, are unpredictable, unexpected, and cannot be determined by conventional animal toxicology.
What Can We Do?
Ace Therapeutics has established an innovative service model based on more than a decade of practical experience and a rich body of research regarding liver knowledge. We provide targeted service solutions based on the uniqueness of predictable DILI and idiosyncratic DILI to fully meet the needs of different clients.
- DILI Pathological Mechanism Research Services
The pathogenesis of DILI is poorly understood due to different diagnostic criteria and lack of reported sample size, which also makes the treatment of DILI extremely difficult. Ace Therapeutics has extensive experience in studying the pathogenesis of the liver. Based on an advanced technology platform and the latest technology, we provide avant-garde services to support your research on the pathogenesis of DILI, including but not limited to
- Role of drug-metabolizing enzyme gene polymorphisms
- Role of human leukocyte antigen (HLA) and other related genes
- Role of liver damage
- Role of hepatocyte oxidative stress
- Role of mitochondrial damage
- Role of inflammatory response
- Role of cell death tissue repair
- Role of immune response
Depending on the different characteristics of predictable DILI and idiosyncratic DILI, we offer different research service solutions.
- For predictable DILI, we provide high-throughput in vitro screening methods that allow preliminary determination of the hepatotoxicity of the drug to be tested. In addition, we provide different animal models to further determine the course of action of the drug to be tested in vivo.
- In terms of idiosyncratic liver injury, several specific drugs have been identified by animal models that cause susceptibility to liver injury. We provide different animal models to obtain more information about idiosyncratic liver injury.
Ace Therapeutics has a dedicated team and extensive hands-on experience in DILI research. We can provide high-quality data and a fast turnaround time to support DILI-related studies. If you would like to learn more about our services, please feel free to contact us.
Reference
- Garcia-Cortes, M., et al., Drug induced liver injury: An update. Arch Toxicol, 2020. 94(10): p. 3381-3407.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
